Pricing Log in Create free account

Cel-Sci Corporation (CVM) vs Metagenomi Therapeutics, Inc. (MGX)

Cel-Sci Corporation and Metagenomi Therapeutics, Inc. are both Biotechnology companies. Cel-Sci Corporation and Metagenomi Therapeutics, Inc. are of similar size ($31.9M and $30.6M). Cel-Sci Corporation grew revenue faster over the last twelve months: 20.8% against −59.8%. Cel-Sci Corporation has the higher net margin (0.00% vs −689.2%) and the lower return on invested capital (−169.6% vs 0.00%). Across the 17 metrics below, Metagenomi Therapeutics, Inc. leads on 9 and Cel-Sci Corporation on 8.

Valuation

Metric CVM MGX Biotechnology median
P/E n/m n/m 8.50
P/S 38.82 2.17 9.71
P/B 1.98 0.26 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.63 0.64
EV/Sales 35.01 (4.50) 9.21
Earnings yield (63.81%) (319.23%) (33.15%)
Free cash flow yield (77.45%) (292.09%) (25.50%)

Profitability

Metric CVM MGX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (741.58%) 0.00%
Net margin 0.00% (689.20%) 0.00%
Free cash flow margin 0.00% (632.67%) 0.00%
Return on equity (252.53%) (60.61%) (56.36%)
Return on assets (108.91%) (41.91%) (48.04%)
Return on invested capital (169.59%) 0.00% 0.00%

Growth

Metric CVM MGX Biotechnology median
Revenue growth (TTM) 20.75% (59.84%) 6.02%
EPS growth (last fiscal year) 59.06% 0.00% 30.26%
Revenue growth, 5-year CAGR 16.18% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CVM MGX Biotechnology median
Debt to equity 0.35 0.00 0.00
Current ratio 1.48 4.50 4.72
Net debt to EBITDA 0.25 1.71 0.96

Dividend

Metric CVM MGX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CVM MGX Biotechnology median
Market cap 30.61m 31.93m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack